Columnist Oluwatosin Adesoye highlights a discrepancy between medical literature and patient experiences regarding ...

Agios Pharmaceuticals is discontinuing development of its oral therapy candidate, tebapivat, for people with sickle cell disease (SCD). The decision follows results from a small Phase 2 clinical trial ...

For a condition that affects millions worldwide, treatment progress for sickle cell disease (SCD) has been slow. In the United States alone, an estimated 100,000 people are living with the disease, ...

Casgevy (exagamglogene autotemcel) is now approved in the U.S. to treat children as young as 2 with sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOCs). The U.S. Food and Drug ...

The U.S. Food and Drug Administration (FDA) has granted priority review — a decision that could speed a drug’s approval — to an application for the oral therapy mitapivat for sickle cell disease (SCD) ...

What began as a season of devastating complications, uncertainty, and hopelessness unexpectedly became the pathway to purpose and career diversification for me. Toward the end of 2017, my life changed ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google One of the hardest things about growing up with sickle cell ...

The prevalence of sickle cell disease (SCD) varies depending on factors like location, race, and ethnicity. Incomplete SCD statistics and data make it difficult to estimate the global burden of the ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google For individuals living with sickle cell disease (SCD), daily life ...

Adesoye Oluwatosin is a practicing physician, a passionate and award-winning sickle cell advocate, and educator. She’s the founder of Sickle Cell Celebs, an online community for people living with ...